Abstract:As a promising radiotherapy technology, stereotactic body radiotherapy (SBRT) enables precise delivery of high-dose radiation in a short course. The characteristic of SBRT is that a high dose outside the target area decreases rapidly, which can ensure the therapeutic dose of the target area and can also minimize the exposure dose of the organ at risk around the target area when compared with regular radiotherapy. Currently, SBRT has become an effective treatment for early stage NSCLC especially for older patients when they are not suitable for operation. We have read with interest this article by Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar about the optimal dose for SBRT in patients with early NSCLC. Moreno et al.1Moreno A.C. Fellman B. Hobbs B.P. et al.Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC.J Thorac Oncol. 2020; 15: 101-109Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar investigated a large cohort with over 20,500 patients. They found that 5-year overall survival (OS) rates were 26% for low biologically effective dose (BED) (BED10 < 130 Gy) and 34% for high BED (BED10 ≥ 130 Gy) groups (p = 0.039), suggesting that a BED10 of 130 Gy and above may confer an additional survival benefit. We would like to point out some concerns regarding this article. First, the authors should consider the competitive risk relationship between cancer-caused death and noncancer-caused death, which is highly related to age. In this article, 70% of patients are more than 70 years old. Thus, noncancer-caused death could be the primary reason for the death toll. Second, we wonder whether the age range was well-balanced between the low-BED and high-BED groups, because the authors only divided patients into two groups (age <70 y and age ≥70 y). We believe that the authors should perhaps need to divide the age into more stratifications (such as <70 y, 75–80 y, 80–85 y, >85 y) or consider the age as a continuous variable in propensity-score matching. Recent studies revealed that SBRT, combined with other treatments, was associated with improved survival. Grinnell et al.2Grinnell M. Appiah A.K. Baine M. et al.Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients [e-pub ahead of print]. J Geriatr Oncol.https://doi.org/10.1016/j.jgo.2020.04.014Google Scholar found adjuvant chemotherapy after SBRT was associated with improved OS in patients more than 70 years old with tumors greater than or equal to 4 cm2. SBRT and immune checkpoint inhibition are rapidly growing and effective treatment modalities.3Käsmann L. Eze C. Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death?.Int J Radiation Oncol Biol Phys. 2020; 108: 225-226Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar In the randomized phase 2 study (PEMBRO-RT) trial, compared with pembrolizumab, SBRT followed by pembrolizumab revealed a doubling of the OS (15.9 mo versus 7.6 mo) and objective response rate (36% versus 18%) in advanced NSCLCs.4Theelen W.S.M.E. Peulen H.M.U. Lalezari F. et al.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial.JAMA Oncol. 2019; 5: 1276-1282Crossref PubMed Scopus (243) Google Scholar These combinations greatly expand the application range of SBRT. As the population ages, there will be a higher proportion of patients who are suitable for SBRT. Therefore, SBRT is a promising method for future clinical applications.

Advances of radiobiology in stereotactic body radiation therapy

Hotspots of Stereotactic Body Radiotherapy in Radiobiology

Advances in Radiobiology of Stereotactic Ablative Radiotherapy

An Overview of the Development of Stereotactic Body Radiation Therapy

Promising Stereotactic Body Radiotherapy in NSCLC

Precision Stereotactic Radiotherapy for Spinal Tumors: Mechanism, Efficacy, and Issues

Precision Stereotactic Radiotherapy for Spinal Tumors: Mechanism, Efficacy, and Issues.

Review of Tumor Radiosensitivity from the Point of View of Stereotactic Ablative Radiotherapy

Stereotactic Ablative Brachytherapy: Recent Advances in Optimization of Radiobiological Cancer Therapy

[Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy]

Clinical Observation of Stereotactic Body Radiation Therapy for Early Stage Non-small Cell Lung Cancer

Clinical observation of stereotactic body radiation therapy guided by cone beam compu-ted tomography for early non-small cell lung cancer

What if a tumor is significantly enlarged just before stereotactic body radiation therapy? A case report and review of the literature

Prognosis And Risk Factors Of Radiation-Induced Lymphopenia In Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy

Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma

Research Advances in Mechanisms for Combination Therapy with Stereotactic Body Radiation Therapy and Immunotherapy

Reirradiation with Stereotactic Body Radiotherapy for Primary or Secondary Lung Malignancies: Tumor Control Probability and Safety Analyses

Dosimetric Evaluations of Different Accelerator Based Treatment Modalities for Curative Intent Stereotactic Body Radiation Therapy of Isolated Thoracic Spinal Metastases

Dose Fractionation of Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer

Proton Pencil-Beam Scanning Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies: Patterns of Practice Survey and Recommendations for Future Development from NRG Oncology and PTCOG

The Critical Role of Stereotactic Body Radiation Therapy in Multimodal Treatment of Lung Metastasis from Bone and Soft Tissue Sarcomas